Display Settings:

Format

Send to:

Choose Destination
Acta Neurol Scand. 2013 Jan;127(1):e1-4. doi: 10.1111/ane.12004. Epub 2012 Sep 5.

Natalizumab treatment during pregnancy - effects on the neonatal immune system.

Author information

  • 1Paediatric Infectious Diseases, University Children's Hospital Mannheim, Heidelberg University, Germany. henriette.schneider@medma.uni-heidelberg.de

Abstract

BACKGROUND:

Pregnancies in women with severe relapsing-remitting multiple sclerosis treated with natalizumab constitute a major challenge, because withdrawal of the drug may cause relapses but continuation might have unknown effects on the infantile immune system.

AIMS OF THE STUDY:

To identify the impact of maternal natalizumab treatment during pregnancy on basic immune functions of the newborn.

METHODS:

Basic immunological testing and assessment of the chemotaxis rate of freshly isolated T lymphocytes in the presence and absence of CXCL12 was performed in two neonates, whose mothers were treated with natalizumab until the 34th week of pregnancy (pw).

RESULTS:

Both children had an uneventful birth. However, a reduction in the CXCL12-induced T-cell chemotaxis was found in both children. In contrast, the chemotaxis rate of unstimulated T lymphocytes was not altered. The distribution of the lymphocyte subpopulations was investigated only in case 1 and was normal.

CONCLUSIONS:

Here, we present to our knowledge the first assessment of T lymphocytes chemotaxis rate in two natalizumab-exposed newborns. A significant reduction in the CXCL12-induced chemotaxis rate of T lymphocytes has been observed and may compromise host defence function in early life. More clinical and immunological data on natalizumab-exposed neonates are warranted.

© 2012 John Wiley & Sons A/S.

PMID:
22950358
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk